Business Description
NewcelX Ltd
ISIN : CH1442297896
Total Employee Number:
11Description
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.2 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.16 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.2 | |||||
3-Year EPS without NRI Growth Rate | 6.2 | |||||
3-Year FCF Growth Rate | 32.5 | |||||
3-Year Book Growth Rate | 247.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.06 | |||||
9-Day RSI | 74.85 | |||||
14-Day RSI | 66.22 | |||||
3-1 Month Momentum % | 47.23 | |||||
6-1 Month Momentum % | 58.85 | |||||
12-1 Month Momentum % | -53.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.76 | |||||
Quick Ratio | 0.76 | |||||
Cash Ratio | 0.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.1 | |||||
Shareholder Yield % | 4.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -194.42 | |||||
ROIC % | -22.72 | |||||
3-Year ROIIC % | 51.24 | |||||
ROC (Joel Greenblatt) % | -2122.22 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.7 | |||||
EV-to-EBIT | -8.78 | |||||
EV-to-EBITDA | -9 | |||||
EV-to-FCF | -7.28 | |||||
Earnings Yield (Greenblatt) % | -11.39 | |||||
FCF Yield % | -12.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NCEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NewcelX Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.16 | ||
| Beta | 2.7992 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 144.26 | ||
| 14-Day RSI | 66.22 | ||
| 14-Day ATR ($) | 0.298532 | ||
| 20-Day SMA ($) | 3.394305 | ||
| 12-1 Month Momentum % | -53.68 | ||
| 52-Week Range ($) | 1.8299 - 7.64 | ||
| Shares Outstanding (Mil) | 5.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NewcelX Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NewcelX Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2025 | 2026-04-29 | 3.35 (-14.10%) | ||
| 0.706:1 Stock Split | 2025-10-31 | 7.17 (+0.00%) | ||
| Annual report for 2024 | 2025-05-16 | 7.17 (+0.00%) | ||
| 0.1:1 Stock Split | 2024-04-01 | 9.07 (+0.00%) |
Show
Entries
NewcelX Ltd Frequently Asked Questions
What is NewcelX Ltd(NCEL)'s stock price today?
The current price of NCEL is $4.08. The 52 week high of NCEL is $7.64 and 52 week low is $1.83.
When is next earnings date of NewcelX Ltd(NCEL)?
The next earnings date of NewcelX Ltd(NCEL) is .
Does NewcelX Ltd(NCEL) pay dividends? If so, how much?
NewcelX Ltd(NCEL) does not pay dividend.
Guru Commentaries on NAS:NCEL
No articles.
Press Release
Articles on NewcelX Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers